抗PD-1/PD-L1单抗的免疫相关不良反应
作者：闫晨霞;张然;王乃栩;
Author：
收稿日期： 年卷（期）页码：2018,33(03):-333-336
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：抗PD-1/PD-L1单抗;免疫检查点抑制剂;免疫治疗;非小细胞肺癌;不良反应;应对措施;综述
Key words：
基金项目：
中文摘要
近年来出现了一种新的非小细包肺癌的免疫治疗方法——免疫检查点抑制剂法。该法具有延长患者生存期、抗肿瘤活性更好、药物使用更安全的优点,但同时也伴有一定的自身免疫相关的不良事件。现参考相关文献,对PD-1/PD-L1抑制剂的应用现状及其不良反应做一综述。
参考文献
[1]Siegel RL,Miller KD,Jemal A.Cancer statistics,2016.[J].CA Cancer J Clin,2016,66(1):7-30.
[2]Jing W,Li M,Zhang Y,et al.PD-1/PD-L1 blockades in non-small-cell lung cancer therapy[J].Onco Targets Ther,2016,9:489-502.
[3]Borghaei H,Brahmer JR,Horn L,et al.Nivolumab vs Docetaxel inpatients withadvanced NSCLC:Check Mate 017/057 2-Y update and exploratory cytokine profile analysis[J].Thorac Oncol,2016,11(10):S237-S238.
[4]Gettinger S,Chow LQ,Borghaei H,et al.Safety and response with Nivolumab(Anti-PD-1;BMS-936558,ONO-4538)plus Erlotinib in patients with epidermal growth factor receptor mutant(EGFR MT)advanced non-small cell lung cancer(NSCLC)[J].Int J Radiat Oncol,2014,90(55):S34-S35.
[5]Hellmann MD,Rizvi NA,Goldman JW,et al.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer(Check Mate 012):Results of an open-label,phase1,multicohort study[J].Lancet Oncolm,2017,18(1):31-41.
[6]Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer(KEYNOTE-010):A randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[7]Fehrenbacher L,Spira A,Ballinger M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):A multicentre,open-label,phase 2randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
[8]Valecha GK,Vennepureddy A,Ibrahim U,et al.Anti-PD-1/PD-L1 antibodies in non-small cellllung cancer:The era of immunotherapy[J].Expert Rev Anticancer Ther,2017,17(1):47-59.
[9]Naidoo J,Page DB,Li BT,et al.Toxicities of the anti-PD-1and anti-PD-L1 immune checkpoint antibodies[J].Ann Oncol,2016,26(12):2375-2391.
[10]Merrill SP,Reynolds P,Kalra A,et al.Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient[J].Ann Pharmacother,2014,48(6):806-810.
[11]Spain L,Diem S,Larkin J.Management of toxicities of immune checkpoint inhibitors[J].Cancer Treat Rev,2016,44:51-60.
【关闭】
